CTOs on the Move

Alexion Pharmaceuticals

www.alexion.com

 
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our shared purpose to serve patients in need drives us to find answers, change the world, and create a legacy. Alexion`s three highly innovative therapies treat patients with four severe and ultra-rare diseases, and we are committed to developing additional therapies that have the potential to transform patients` lives. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.alexion.com
  • 100 College Street
    New Haven, CT USA 06510
  • Phone: 203.271.8198

Executives

Name Title Contact Details
Rick Braun
Associate Director, Go-to-Market IT Business Partner Profile
Lauren Iacono
Head of Digital and Social Communications Profile
Craig Mansfield
Director, Global Head of Security and Facilities Operations Profile
Frederic Lancaster
Deputy Chief Information Security Officer Profile
Susan Tyson
Associate Director - Security Business Solutions Profile

Similar Companies

Chi Botanic

Changing how we grow with plant cell cultures.

SiChuan Sanherb Biotech

SiChuan Sanherb Biotech is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Logical Therapeutics

Logical Therapeutics is a Foxboro, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allied Safety Associates

Allied Safety Associates is a West Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.